ATE539063T1 - Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen - Google Patents

Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen

Info

Publication number
ATE539063T1
ATE539063T1 AT08759158T AT08759158T ATE539063T1 AT E539063 T1 ATE539063 T1 AT E539063T1 AT 08759158 T AT08759158 T AT 08759158T AT 08759158 T AT08759158 T AT 08759158T AT E539063 T1 ATE539063 T1 AT E539063T1
Authority
AT
Austria
Prior art keywords
regioselective
azabenzimidazoles
benzimidazoles
copper
catalyzed synthesis
Prior art date
Application number
AT08759158T
Other languages
German (de)
English (en)
Inventor
Jorge Alonso
Andreas Lindenschmidt
Marc Nazare
Matthias Urmann
Nis Halland
Kyek Omar R
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE539063T1 publication Critical patent/ATE539063T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08759158T 2007-06-26 2008-06-11 Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen ATE539063T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290800 2007-06-26
PCT/EP2008/004639 WO2009000413A1 (en) 2007-06-26 2008-06-11 A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles

Publications (1)

Publication Number Publication Date
ATE539063T1 true ATE539063T1 (de) 2012-01-15

Family

ID=38646504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08759158T ATE539063T1 (de) 2007-06-26 2008-06-11 Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen

Country Status (12)

Country Link
US (1) US8735586B2 (OSRAM)
EP (1) EP2173721B1 (OSRAM)
JP (1) JP5492770B2 (OSRAM)
KR (1) KR20100023907A (OSRAM)
CN (1) CN101687815A (OSRAM)
AT (1) ATE539063T1 (OSRAM)
AU (1) AU2008267444A1 (OSRAM)
BR (1) BRPI0813271A2 (OSRAM)
CA (1) CA2691857A1 (OSRAM)
IL (1) IL202823A0 (OSRAM)
MX (1) MX2009013753A (OSRAM)
WO (1) WO2009000413A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
SG181947A1 (en) 2009-12-30 2012-07-30 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds
PL2610255T3 (pl) * 2010-08-25 2016-08-31 Neopharm Co Ltd Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych
PT2624696T (pt) 2010-10-06 2017-03-21 Glaxosmithkline Llc Derivados de benzimidazole como inibidores da cinase pi3
ES2571741T3 (es) 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
KR20190015600A (ko) 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US9156838B2 (en) * 2012-06-22 2015-10-13 Sumitomo Chemical Company, Limited Fused heterocyclic compound
CN102924460B (zh) * 2012-11-05 2015-12-16 南京师范大学 一种4H-吡咯并[1,2-a]苯并咪唑衍生物及其合成方法和应用
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN103130811B (zh) * 2013-03-11 2015-02-25 河南师范大学 一种5,6-二氢吡唑并[1,5-c]喹唑啉类化合物的合成方法
US9695149B2 (en) 2013-03-15 2017-07-04 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
WO2014140365A1 (en) * 2013-03-15 2014-09-18 Syngenta Participations Ag Microbicidally active imidazopyridine derivatives
US9067917B2 (en) 2013-03-15 2015-06-30 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as FLAP modulators
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
CN106163527A (zh) 2013-11-22 2016-11-23 Cl生物科技有限责任公司 用于治疗和预防骨质疏松症的胃泌素拮抗剂
CN103965136B (zh) * 2014-05-07 2016-09-07 苏州波菲特新材料科技有限公司 一种制备n-甲基噻唑啉-2-酮类化合物的方法
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
CN106519250A (zh) * 2016-09-29 2017-03-22 辽宁石油化工大学 含氮小分子有机配体调节荧光发射性质的一维链状铜配位聚合物的制备方法
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP4311577A3 (en) 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CN110536890B (zh) 2017-04-26 2023-08-15 巴斯利尔药物国际股份公司 制备呋咱并苯并咪唑及其晶型的方法
CN111065383A (zh) 2017-07-11 2020-04-24 沃泰克斯药物股份有限公司 用作钠通道调节剂的羧酰胺
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
GB201800688D0 (en) 2018-01-16 2018-02-28 Redag Crop Prot Ltd Agricultural chemicals
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
CN110982806B (zh) * 2019-08-30 2022-09-02 浙江工业大学 一种蛋白质芳基衍生物及其制备方法
LT4069691T (lt) 2019-12-06 2024-12-10 Vertex Pharmaceuticals Incorporated Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai
CN111206260B (zh) * 2020-02-12 2022-03-22 齐鲁工业大学 一种吡啶并[1,2-a]苯并咪唑类化合物的电化学合成方法
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072146A1 (en) * 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
KR20090097908A (ko) * 2006-12-06 2009-09-16 베링거 인겔하임 인터내셔날 게엠베하 글루코코르티코이드 모사물, 이의 제조 방법, 이의 약제학적 조성물 및 용도

Also Published As

Publication number Publication date
US8735586B2 (en) 2014-05-27
JP5492770B2 (ja) 2014-05-14
EP2173721A1 (en) 2010-04-14
WO2009000413A1 (en) 2008-12-31
CA2691857A1 (en) 2008-12-31
CN101687815A (zh) 2010-03-31
AU2008267444A1 (en) 2008-12-31
BRPI0813271A2 (pt) 2014-12-30
US20100261909A1 (en) 2010-10-14
IL202823A0 (en) 2010-06-30
MX2009013753A (es) 2010-01-26
EP2173721B1 (en) 2011-12-28
KR20100023907A (ko) 2010-03-04
JP2010531313A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
ATE539063T1 (de) Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen
BRPI0813273A2 (pt) Síntese catalisada por metal regiosseletivo de benzimidazóis e azabenzimidazóis anelados
ATE544757T1 (de) Regioselektive, palladiumkatalysierte synthese von benzimidazolen und azabenzimidazolen
EA201171211A1 (ru) Производные оксадиазола
ATE511501T1 (de) Übergangsmetallkatalysierte synthese von 2h- indazolen
EA201070238A1 (ru) Соединения пиримидина
EA201070422A1 (ru) Производные оксадиазола
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2009006730A (es) Derivados de n-(5, 6, 7, 8-tetrahidronaftalen-1-il) urea y compuestos relacionados como antagonistas de receptor vaniloide trpv1 par el tratamiento de dolor.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
ATE537142T1 (de) Übergangsmetallkatalysierte synthese von n- aminoindolen
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
CO6190517A2 (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
MX2010007019A (es) Compuestos de bencimidazol.
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
MX2012006696A (es) Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina.
MA32788B1 (fr) 1-(arylsulfonyl)-4-(piperazine-1-yl)-1h-benzimidazoles servant de ligands de la 5-hydroxytryptamine-6
BRPI0812829A2 (pt) Processo para o acoplamento catalisado por paládio de alcinas terminais com tosilatos de arila
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists